Keerthi Talari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keerthi Talari has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Vinod Ravindran
Centre for Rheumatology , Kozhikode, Keralam
4 shared publications - Arun Kumar Sharma
SMS Hospital & Medical College, Jaipur, Rajasthan, India
1 shared publication - Himanshu Pathak
Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK
1 shared publication - Jijy Abraham
Stempeutics Research Private Limited, Bangalore, India
1 shared publication - Joe Joseph Cherian
St. John's Medical College, Bangalore, Karnataka, India
1 shared publication - Laura Andreoli
University of Brescia
1 shared publication
Latest Publications
- 5 November 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (11)
Beyond Consensus: Translating the APLAR Reproductive Rheumatology Recommendations Into Measurable Care Across the Asia‐Pacific Region
- 5 November 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (11)
Beyond Consensus: Translating the APLAR Reproductive Rheumatology Recommendations Into Measurable Care Across the Asia‐Pacific Region
- 30 June 2026
- Published by Springer Nature
- p. 407-425
Digital Health in Reproductive Rheumatology
- Open Access
- 11 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (1) , 100723
Two years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study
- 11 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (1) , 100723
Open AccessTwo years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study
- 17 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70329
Gender Inequality in Access to Rheumatology Care in APLAR Countries: Outcomes and Potential Solutions
- 17 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70329
Gender Inequality in Access to Rheumatology Care in APLAR Countries: Outcomes and Potential Solutions
- 23 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 4869-4871
Artificial intelligence-driven categorization of rheumatological disease subgroups
- 23 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 4869-4871
Artificial intelligence-driven categorization of rheumatological disease subgroups
- 3 March 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (2) , 102052
Access to rheumatologic care in tropical regions: Barriers and solutions
- 3 March 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (2) , 102052
Access to rheumatologic care in tropical regions: Barriers and solutions
- 24 November 2023
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 53 (4) , 232-236
Predatory journals: How to recognise and keep clear!
Predatory publishing poses a major threat to the integrity of academic research. While publication in scientific journals has traditionally been a hallmark of authentic information, the 'publish or perish' culture has fuelled and enhanced the growth of predatory journals. Predatory publishers prioritise profit over academic integrity, often charge exorbitant fees for a nearly non-existent peer review. Lack of awareness, pressure to publish and the prohibitive cost of open-access publishing contribute to the dubious cause of predatory journals. Identifying predatory journals is essential, and multiple resources exist to assist in identifying them.
- 24 November 2023
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 53 (4) , 232-236
Predatory journals: How to recognise and keep clear!
Predatory publishing poses a major threat to the integrity of academic research. While publication in scientific journals has traditionally been a hallmark of authentic information, the 'publish or perish' culture has fuelled and enhanced the growth of predatory journals. Predatory publishers prioritise profit over academic integrity, often charge exorbitant fees for a nearly non-existent peer review. Lack of awareness, pressure to publish and the prohibitive cost of open-access publishing contribute to the dubious cause of predatory journals. Identifying predatory journals is essential, and multiple resources exist to assist in identifying them.
- 1 May 2021
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 16 (1S) , 87-91
Management of Connective Tissue Disease-Associated Interstitial Lung Disease
Evidence guiding management of CTD-ILD with a specific focus on corticosteroids, cyclophosphamide, mycophenolate, azathioprine, calcineurin inhibitors, and pirfenidone. Corticosteroids (except in systemic sclerosis [SSc]-ILD) in combination with immunosuppressants form the mainstay of therapy in CTD-ILD. Cyclophosphamide and mycophenolate mofetil are backed by randomised trials-Scleroderma lung study I and II respectively for SSc-ILD, while calcineurin inhibitors with or without cyclophosphamide have emerged as a promising initial therapy in myositis associated ILD. Rituximab is probably beneficial for all forms of CTD-ILD even as randomized trial data are awaited. General measures such as lifestyle modification, pulmonary rehabilitation, vaccination, prophylaxis, supplemental oxygen, palliative care are also of paramount importance. Future research should focus on long-term efficacy, safety and head-to-head comparison of drugs, role of upfront combination therapies, supportive and palliative care....
- 1 May 2021
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 16 (1S) , 87-91
Management of Connective Tissue Disease-Associated Interstitial Lung Disease
Evidence guiding management of CTD-ILD with a specific focus on corticosteroids, cyclophosphamide, mycophenolate, azathioprine, calcineurin inhibitors, and pirfenidone. Corticosteroids (except in systemic sclerosis [SSc]-ILD) in combination with immunosuppressants form the mainstay of therapy in CTD-ILD. Cyclophosphamide and mycophenolate mofetil are backed by randomised trials-Scleroderma lung study I and II respectively for SSc-ILD, while calcineurin inhibitors with or without cyclophosphamide have emerged as a promising initial therapy in myositis associated ILD. Rituximab is probably beneficial for all forms of CTD-ILD even as randomized trial data are awaited. General measures such as lifestyle modification, pulmonary rehabilitation, vaccination, prophylaxis, supplemental oxygen, palliative care are also of paramount importance. Future research should focus on long-term efficacy, safety and head-to-head comparison of drugs, role of upfront combination therapies, supportive and palliative care....
- Open Access
- 29 July 2016
- Published by MedCrave Group Kft. in MOJ Orthopedics & Rheumatology
- Vol. 5 (3) , 1-4
Biosimilars in Rheumatology: an Indian Scenario
With the introduction of biologics, there has been significant improvement in response in rheumatologic disorders like rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. As most of these biologics have approached patent expiry, follow on versions called biosimilars have been introduced. Though only two of them have been approved by the EMA and one by the FDA, quite a few have been introduced in India. The process of approval of bio similars requires strict regulations to demonstrate efficacy, purity and safety. Preclinical, clinical (pharmacokinetic, pharmacodynamics, efficacy and safety) studies are to be done before their approval. Currently, five biosimilars used in rheumatology are approved in India. This review discusses the process of development of a biosimilar, regulatory guidelines in their approval process in India and the current status of biosimilars in rheumatology in India.
- 29 July 2016
- Published by MedCrave Group Kft. in MOJ Orthopedics & Rheumatology
- Vol. 5 (3) , 1-4
Open AccessBiosimilars in Rheumatology: an Indian Scenario
With the introduction of biologics, there has been significant improvement in response in rheumatologic disorders like rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. As most of these biologics have approached patent expiry, follow on versions called biosimilars have been introduced. Though only two of them have been approved by the EMA and one by the FDA, quite a few have been introduced in India. The process of approval of bio similars requires strict regulations to demonstrate efficacy, purity and safety. Preclinical, clinical (pharmacokinetic, pharmacodynamics, efficacy and safety) studies are to be done before their approval. Currently, five biosimilars used in rheumatology are approved in India. This review discusses the process of development of a biosimilar, regulatory guidelines in their approval process in India and the current status of biosimilars in rheumatology in India.